ArticleMolecular biology reports2025
Antitumor and analgesic activity of sinningia reitzii compounds in breast cancer models.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBreast cancer is the most frequent in women for both cases and deaths and at least half of patients report pain as a symptom. A previous phytochemical study with the tubers of the Sinningia reitzii (Hoehne) L.E.Skog (SR) led to the isolation of 8 naphthoquinones. Among them, the 6,7-dimethoxydunnione (SR4) showed antitumor activity in vitro. This study aimed to evaluate the antitumor and analgesic potential of SR components against Ehrlich carcinoma in Swiss female mice, and in MCF-7 and HB4a breast cell lineages.
methodsMice were inoculated with tumor cells and treated daily with SR extract, namely dichloromethane fraction (ESR, 10, 30 and 100 mg kg− 1), SR4 (3 mg kg− 1) or vehicle, orally; or with the methotrexate chemotherapy (2.5 mg kg− 1) via i.p., every 3 days, along 21 days.
resultsBoth ESR and SR4 induced toxicity in the tumor cell MCF-7 but did not in non-tumor human breast cell HB4a in culture. ESR and SR4 showed antitumor effects, but ESR showed more expressive results. The ESR caused changes in the oxidative balance in the tumor tissue and decreased myeloperoxidase levels without reducing the levels of pro-inflammatory cytokines. ESR induced necrosis in tumor and increased the gene expression of Ripk1, which is involved in the necroptosis pathway. In addition, ESR showed acute, but not cumulative, analgesic effect in pain associated with Ehrlich cells inoculation in the mice paw.
conclusionsThe components of Sinningia reitzii, mainly the ESR, are promising sources of drugs that combine analgesic and antitumor effects, without systemic toxicity.
Indexed as
Identifiers
41369853What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.